Pharmaceutical companies that pioneered the listing of A-share unprofitable companies disclosed their semi-annual reports and continued to lose money in the first half of the year.

"Pharmaceutical Network Enterprise News" January 23, 2020, Suzhou Zeyi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zeyi Pharmaceuticals") successfully listed on the Science and Technology Board, becoming the fifth set of listing standards selected by the head of the Science and Technology Board enterprises, but also created an A-share non-income unprofitable enterprises listed first.
now, as listed companies continue to report their 2020 half-year results, the high-profile drug company has finally handed over its 2020 half-year results: continued losses in the first half of the year.
On the evening of August 16th, Ze-Yuan Pharmaceuticals disclosed its 2020 semi-annual report, showing that during the reporting period, the company had not realized operating income and had a net profit loss attributable to shareholders of listed companies of 129 million yuan, a decrease of 213 million yuan year-on-year.
net profit net profit net loss of 144 million yuan, net loss increased by 2.3453 million yuan year-on-year.
reporting period, the company's total assets were about 2,039 million yuan, up 536.70 percent year-on-year.
For the reasons for the continued losses in the first half of the year, the announcement pointed out that the main reason is that the company's initial new drugs are still in the registration application for approval, the development of various new drugs continue to advance, a number of innovative drugs in the clinical trial research stage, research and development expenditure is larger.
company expects to have accumulated unrepared losses and continuing losses for some time to come.
note that during the reporting period, the company increased its investment in research and development, which was greater than the total net profit loss.
first half of 2020, the company invested 129 million yuan in research and development, an increase of 70.84 percent year-on-year.
, the commissioned preclinical trial service fee increased by 123.27% YoY and the commissioned clinical trial service fee increased by 208.53% YoY.
, the company actively carried out various work in the first half of the year, vigorously promoted the clinical trial process, the product pipeline made positive progress.
As of the date of disclosure of the report, Zee-Pharma has 30 research projects in research and development of 12 main drugs in research, of which 5 are in the NDA, II/III phase clinical trial stage, in phase I/II clinical trials, IND stage of one drug in research, and 5 are in the preclinical research and development stage.
It is known that new drugs in the clinical research stage include toluene sulfonate donafinib tablets, external recombinant human coagulase, hydrochloric acid jactictin tablets, oxateni capsules, injection recombinant human thyroid hormone and hydrochloric acid jacktinie cream.
addition, ZG5266 is in the IND application stage.
small molecule new drug ZG0588 and ZG170607, anti-tumor dual-target antibody new drug ZG005 and ZG006, anti-tumor three-target antibody ZGGS001 in the pre-clinical research and development stage.
also in the research and development process of new drugs, the treatment of liver cancer targeted treatment of the new drug Donaphini research and development process is relatively fast, the variety was in May 2020 to obtain the new drug market application for formal acceptance.
notable, Donaphini has become the first-line treatment drug for advanced liver cell carcinoma (HCC) recommended in the new Edition of the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer, and has also received a first-line recommendation from CSCO.
cancer is the second largest cause of cancer death in China, with nearly half of all new cases and deaths in China in 2018 reaching nearly 400,000 people.
Because liver cancer has no specific symptoms in the early stages, about 80% of liver cancer patients miss out on early treatment opportunities, and even if some patients undergo curing surgery, more than half of them will metas or return within five years, affecting their long-term survival.
industry believes that Donaphini broke the Chinese liver cancer targeted drug market dominated by imported drugs, while as a target treatment for liver cancer treatment of new drugs, the future is expected to usher in the release.
.